Open AccessAntiviral treatment of COVID-19: a clinical pharmacology narrative review
Author(s) -
Instiaty,
I Gusti Agung Ayu Putu Sri Darmayani,
Jefman Efendi Marzuki,
Ferina Angelia,
William William,
Angelina Siane,
Lela Dwi Sary,
Lina Yohanes,
Reni Widyastuti,
Riki Nova,
Dewi Sharon Simorangkir,
Lonah Lonah,
Yolanda Safitri,
Gestina Aliska,
Anggi Gayatri
Publication year - 2020
Publication title -
medical journal of indonesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.164
H-Index - 9
eISSN - 2252-8083
pISSN - 0853-1773
DOI - 10.13181/mji.rev.204652
Subject(s) - lopinavir , hydroxychloroquine , medicine , ritonavir , repurposing , chloroquine , favipiravir , drug repositioning , pharmacology , adverse effect , oseltamivir , covid-19 , pandemic , drug , intensive care medicine , virology , malaria , disease , viral load , immunology , virus , infectious disease (medical specialty) , ecology , antiretroviral therapy , biology
The outbreak of coronavirus disease 2019 (COVID-19) in December 2019 in China, has become a pandemic in March 2020 Repurposing old and relatively safe drugs becomes an advantageous option to obtain the urgently needed effective treatment Repurposing chloroquine, hydroxychloroquine, oseltamivir, lopinavir/ritonavir, and favipiravir, and the use of investigational drug remdesivir for treatment of COVID-19, are reviewed from the clinical pharmacology perspective, particularly its efficacy and safety Limited clinical studies of chloroquine, hydroxychloroquine, favipiravir, and remdesivir showed some efficacy in COVID-19 treatment with tolerable adverse effects Potential serious adverse effect of chloroquine and hydroxychloroquine is cardiac arrhythmia Oseltamivir has no documented activity against SARS-CoV-2, while lopinavir/ritonavir showed limited efficacy in COVID-19 Currently, there is no sufficient evidence to recommend any specific anti-COVID-19 treatment The decision to use these drugs during the COVID-19 pandemic must be based on careful consideration of the potential benefits and risks to the patient
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom